Clinical characteristics of patients with sclerodermatous cGVHD
| Characteristic . | Value . |
|---|---|
| No. of patients | 8 |
| Sex | |
| Female, % | 4 (50) |
| Male, % | 4 (50) |
| Age of recipient, y, mean ± SD | 51.3 ± 13.2 |
| Age of donor, y, mean ± SD | 48.2 ± 12.5 |
| Time between HSCT and onset of cGVHD, y, mean ± SD | 8.7 ± 2.1 |
| Site biopsy | |
| Thigh, % | 6 (75) |
| Forearm, % | 2 (25) |
| Therapy | |
| CsA, % | 2 (25) |
| MMF, % | 7 (87) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 8 |
| Sex | |
| Female, % | 4 (50) |
| Male, % | 4 (50) |
| Age of recipient, y, mean ± SD | 51.3 ± 13.2 |
| Age of donor, y, mean ± SD | 48.2 ± 12.5 |
| Time between HSCT and onset of cGVHD, y, mean ± SD | 8.7 ± 2.1 |
| Site biopsy | |
| Thigh, % | 6 (75) |
| Forearm, % | 2 (25) |
| Therapy | |
| CsA, % | 2 (25) |
| MMF, % | 7 (87) |
HSCT indicates hematopoietic stem cell transplantation; CsA, cyclosporine A; and MMF, mycophenolate mofetil.